Literature DB >> 29944887

Long noncoding RNA LINC00858 promotes osteosarcoma through regulating miR-139-CDK14 axis.

Zenghui Gu1, Zhenhai Hou2, Longbao Zheng2, Xinqiang Wang2, Liangbang Wu2, Cheng Zhang2.   

Abstract

Long noncoding RNAs (lncRNAs) have been identified to modulate the tumorigenesis of human cancers. The in-depth of lncRNAs on human osteosarcoma oncogenesis is still ambiguous. In present study, functional and mechanism experiments were conducted to investigate the role of long intergenic non-protein coding RNA 00858 (LINC00858) on human osteosarcoma tumorigenesis. Results demonstrated that LINC00858 expression was significantly upregulated in both osteosarcoma tissues and cell lines. Mechanism assays presented that LINC00858 silencing significantly repressed osteosarcoma cells' proliferation and invasion in vitro, and inhibited the tumor growth in vivo. In further experiments, LINC00858 was identified to sponge miR-139 to form RNA-induced silencing complex (RISC) using luciferase reporter assay and RNA immunoprecipitation (RIP). Besides, CDK14 was validated to be the target protein the miR-139. Rescue experiments confirmed the role of LINC00858/miR-139/CDK14 pathway on osteosarcoma cells' phenotype. In summary, these data prove that LINC00858/miR-139/CDK14 axis promotes the tumorigenesis of osteosarcoma, providing a new mechanism or target for osteosarcoma.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CDK14; LINC00858; Osteosarcoma; ceRNA; miR-139

Mesh:

Substances:

Year:  2018        PMID: 29944887     DOI: 10.1016/j.bbrc.2018.06.131

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Long non-coding RNA LINC00858 aggravates the oncogenic phenotypes of ovarian cancer cells through miR-134-5p/RAD18 signaling.

Authors:  Heng Xue; Zhihui Wu; Dongdong Rao; Bimin Zhuo; Qingquan Chen
Journal:  Arch Gynecol Obstet       Date:  2020-09-01       Impact factor: 2.344

2.  Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4α and WNK2 regulation.

Authors:  Ting Xu; Kun Wu; Lei Zhang; Shutao Zheng; Xiaopeng Wang; Hao Zuo; Xu Wu; Guoquan Tao; Baofei Jiang; Li Zhang
Journal:  Cell Oncol (Dordr)       Date:  2019-12-28       Impact factor: 6.730

3.  The long non-coding RNA-ROR promotes osteosarcoma progression by targeting miR-206.

Authors:  Dan Fei; Guoqing Sui; Yang Lu; Long Tan; Zhao Dongxu; Kewei Zhang
Journal:  J Cell Mol Med       Date:  2018-12-19       Impact factor: 5.310

4.  LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.

Authors:  Jun Liu; Tao Tang; Guo-Dong Wang; Bo Liu
Journal:  Biosci Rep       Date:  2019-07-15       Impact factor: 3.840

Review 5.  Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma.

Authors:  Zihe Dong; Zhipeng Liao; Yonglin He; Chengye Wu; Zixiang Meng; Baolong Qin; Ge Xu; Zeyang Li; Tianxin Sun; Yuyan Wen; Guangjie Li
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Integrated analysis of lymphocyte infiltration-associated lncRNA for ovarian cancer via TCGA, GTEx and GEO datasets.

Authors:  Meijing Wu; Xiaobin Shang; Yue Sun; Jing Wu; Guoyan Liu
Journal:  PeerJ       Date:  2020-05-07       Impact factor: 2.984

7.  LINC00858 promotes retinoblastoma cell proliferation, migration and invasion by inhibiting miR-3182.

Authors:  Qi Wang; Yanni Zhu; Guojin Zuo; Xiaoming Chen; Jinkui Cheng; Shu Zhang
Journal:  Exp Ther Med       Date:  2019-12-05       Impact factor: 2.447

Review 8.  Osteosarcoma and Metastasis.

Authors:  Gaohong Sheng; Yuan Gao; Yong Yang; Hua Wu
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

9.  Long non-coding RNA CRNDE regulates the growth and migration of prostate cancer cells by targeting microRNA-146a-5p.

Authors:  Dewang Fu; Li'e Zang; Zhaowei Li; Chenghui Fan; Huamao Jiang; Tongyi Men
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.